Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Current and Future Landscape of Hepatocellular Carcinoma Treatment.Oncology research · 2026
   Review
2. Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity.Heliyon · 2024
   Article
3. Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering.Frontiers in pharmacology · 2023
   Review
4. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort.Liver cancer · 2021
   Article
5. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.Scientific reports · 2021
   Article
6. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials.Frontiers in oncology · 2021
   Review
7. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.Liver cancer · 2020
   Review
8. Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma.Liver cancer · 2020
   Article
9. LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway.Cancer management and research · 2020
   Article
10. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.World journal of gastroenterology · 2019
    Review
11. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.Targeted oncology · 2019
    Review
12. Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis.Therapeutic advances in gastroenterology · 2019
    Article
13. New generation cancer therapy: right direction for sure with some uncertainty.Hepatology international · 2019
    Article
14. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.Cancers · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.